Newsroom | 15806 results

SAN FRANCISCO--(BUSINESS WIRE)--Chegg, Inc. (NYSE:CHGG), a global learning company, today announced that on March 13, 2026 (“Grant Date”), its Compensation Committee granted equity awards pursuant to the Chegg 2023 Equity Inducement Plan (the “Plan”). One newly hired employee received a grant of restricted stock units (“RSUs”) representing 150,000 shares of Chegg common stock (“Shares”) in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The...

WARWICK, R.I.--(BUSINESS WIRE)--PeopleGrove, the leading SaaS platform for experiential learning and engagement in higher education, today announced the launch of new features and functionality within its trusted CORE for Education product suite. New capabilities include native field encounter videos, enhanced digital binders, and integrated competency management powered by responsible AI. CORE by PeopleGrove brings video, complex placement management, and competency data in a single, unified s...

TAMPA, Fla.--(BUSINESS WIRE)--CyberBay today announced the winner of the CyberBay Innovation Challenge, awarding a $70,000 non-dilutive grant to Actualization.ai and its SquarePact solution for its innovative approach to making cybersecurity more accessible, usable, and effective for small and mid-sized organizations. The winner was selected following live pitches from three finalist companies during CyberBay Summit 2026, where founders presented their solutions to a panel of industry judges. A...

BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the fourth quarter and full-year period ended December 31, 2025. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Fourth Quarter 2025 Highlights 4Q25 Revenue...

BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced that its board of directors (the “Board”) approved its second distribution of a cash dividend. On March 12, 2026, the Company’s Board of Directors approved dividend distribution in the amount of R$307.4 million, representing 40% of the Company’s consolidated net income for the year ended Decem...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (hoofdzetel: Chuo-ku, Tokio, Japan; voorzitter en vertegenwoordigend directeur: Toshiaki Nagasato) maakte vandaag bekend dat het bedrijf een klinische studie van Fase I van ME3241 (ontwikkelingscode) is gestart, een anti-PD-1-agonist monoklonaal antilichaam ontdekt via onderzoek in samenwerking met de FBRI (Foundation for Biomedical Research & Innovation) in Kobe (hoofdzetel: Kobe, Japan; voorzitter: Shuh Narumiya; hierna aangeduid als “F...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (sede centrale: Chuo-ku, Tokyo, Giappone; Presidente e direttore rappresentante delegato: Toshiaki Nagasato) ha annunciato oggi di aver avviato lo studio clinico di Fase I di ME3241 (codice di sviluppo), un anticorpo monoclonale agonista anti-PD-1 scoperto grazie alla ricerca collaborativa condotta con la Foundation for Biomedical Research and Innovation di Kobe (sede centrale: Kobe, Giappone; Presidente: Shuh Narumiya; di seguito "FBRI"). Lo...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (sede central: Chuo-ku, Tokio, Japón; presidente y director representante: Toshiaki Nagasato) acaba de anunciar el inicio de un ensayo clínico de fase I con ME3241 (código de desarrollo), anticuerpo monoclonal agonista anti-PD-1 descubierto gracias a la investigación llevada a cabo junto con la Foundation for Biomedical Research and Innovation at Kobe (sede central: Kobe, Japón; presidente: Shuh Narumiya; en adelante, «FBRI»). Este ensayo clí...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (siège : Chuo-ku, Tokyo, Japon ; Président-directeur général : Toshiaki Nagasato) a annoncé aujourd’hui avoir lancé un essai clinique de phase I sur le ME3241 (code de développement), un anticorps monoclonal agoniste anti-PD-1 découvert dans le cadre d’une recherche collaborative avec la Fondation pour la recherche biomédicale et l’innovation à Kobe (siège social : Kobe, Japon ; président : Shuh Narumiya ; ci-après « FBRI »). L’essai clinique...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Hauptsitz: Chuo-ku, Tokio, Japan; President und Representative Director: Toshiaki Nagasato) gab heute den Start einer klinischen Phase-I-Studie mit ME3241 (Entwicklungscode) bekannt. Bei diesem Wirkstoff handelt es sich um einen monoklonalen Anti-PD-1-Agonisten-Antikörper, der im Rahmen einer Forschungszusammenarbeit mit der Foundation for Biomedical Research and Innovation at Kobe (Hauptsitz: Kobe, Japan; President: Shuh Narumiya; nachstehe...